DMARDs and Incidence of Virus-Associated Malignancy in RA
In this study, biologic DMARD therapy was not associated with an increased incidence of virus-associated cancers in female patients with inflammatory arthritis.
Psoriatic Arthritis
Long Term Safety Data for Apremilast in Psoriatic Arthritis and Psoriasis
Celgene announced long-term safety data for Otezla (apremilast) from ongoing clinical trials at the American Academy of Dermatology’s Annual Meeting.
Are Biosimilars About to Make Waves in Rheumatology?
The growing use of expensive biologics has led public and private insurers in the United States to impose cost-sharing burdens that place these drugs out of reach for many patients. The FDA is anticipating a marked increase in the biosimilar market as more patents expire for brand-name biologics.
No Significant Increased Risk of Birth Defects in Offspring of Women on Anti-TNF Agents
Women who received anti-TNF agents during pregnancy did not have a significantly higher risk of having children with birth defects.
Digital X-ray: Different Periarticular Hand BMD In PsA and RA After Antirheumatic Treatment
Researchers have found that following antirheumatic treatment, individuals with RA demonstrated ongoing bone loss in their hands, but those with PsA maintained their periarticular BMD. This suggests that different mechanisms are involved in bone remodeling of the hand in PsA.
Factors Predicting Biologic Discontinuation in Inflammatory Rheumatic Disease
Self-discontinuation of biologic medication was associated with 5 predictive factors. Routine assessment for these specific factors in patients with chronic inflammatory rheumatic disease being treated with biologics may increase adherence to treatment.
Enteropathic Spondyloarthritis: A Review of Mechanisms and Effective Treatment Strategies
Enteropathic spondyloarthritis (ESpA) encompasses a group of rheumatic disorders that share overlapping pathophysiology with other immune system disorders, particular those of the gut. Therefore, a multidisciplinary approach is important to recognizing the varied manifestations of ESpA in patients with IBD in order to achieve a prompt and accurate diagnosis leading to comprehensive care.
Golimumab Improves Long-Term Radiographic Outcomes in Psoriatic Arthritis
Results from the GO-REVEAL trial indicate that golimumab treatment is associated with long-term improvement in psoriatic arthritis.
Prognostic Utility of Antibodies to Adalimumab in RA, AS, and PsA
Study assessed the development of antibodies to adalimumab as a diagnostic indicator in rheumatoid arthritis, ankylosing spondylosis, and psoriatic arthritis.
Cytokine Converter Cell Implants Offer a Translational Approach to Treating Psoriasis and Other Chronic Immune Disorders
Normal skin tissue morphology restored in psoriatic mice implanted with microencapsulated cytokine converter transgenic designer cells.
-
Loading...
-
Loading...
Next post in Psoriatic Arthritis
